Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $11.5K | $3.75K |
| Revenue growth | — | — | — | -67.4% |
| Gross profit | — | $0.00 | $1.83K | -$3.50K |
| Gross margin | — | — | 15.9% | -93.4% |
| Operating income | — | -$56.4K | — | — |
| Net income | — | -$56.4K | -$25.8K | $51.4K |
| Net margin | — | — | -224.4% | 1370.5% |
| EPS (diluted) | — | $0.00 | $0.00 | $0.00 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | — | -$38.1K | -$12.5K | -$4.53K |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $10.1K | $7.86K | $1.03K | $0.00 |
| Total assets | $54.0K | $37.0K | $27.5K | $0.00 |
| Total liabilities | $54.4K | $66.1K | $82.3K | $0.00 |
| Shareholders' equity | -$437.00 | -$29.1K | -$54.9K | $0.00 |
| Retained earnings | -$937.00 | -$57.4K | -$83.2K | -$31.8K |
| Shares (wtd avg diluted) | 5.00M | 5.69M | 7.78M | 7.78M |
Every figure is extracted from Exousia Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.